ExploreWatchlistsPricing
  1. JP-listed companies
  2. SanBio Company Limited
  3. Financials
  4. Total non-current liabilities

SanBio Company Limited (4592)

Market cap
¥159.8B
P/E ratio
-28.4x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal non-current liabilities (Million JPY)YoY (%)
Jan 31, 20261,483+55.68%
Jan 31, 2025952-29.42%
Jan 31, 20241,349-11.58%
Jan 31, 20231,526-24.18%
Jan 31, 20222,013-20.30%
Jan 31, 20212,525-27.86%
Jan 31, 20203,500-12.50%
Jan 31, 20194,000+79.10%
Jan 31, 20182,233+94.20%
Jan 31, 20171,150+137.15%
Jan 31, 2016485-66.83%
Jan 31, 20151,462

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat